Explore the words cloud of the GlycoMabs project. It provides you a very rough idea of what is the project "GlycoMabs" about.
The following table provides information about the project.
Coordinator |
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Organization address contact info |
Coordinator Country | Spain [ES] |
Total cost | 160˙932 € |
EC max contribution | 160˙932 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2018 |
Funding Scheme | MSCA-IF-EF-RI |
Starting year | 2019 |
Duration (year-month-day) | from 2019-04-16 to 2021-04-15 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS | ES (DERIO VIZCAYA) | coordinator | 160˙932.00 |
Monoclonal Antibodies (mAbs) have gained an important place in the therapeutic arsenal of anticancer drugs. mAbs are glycoproteins containing a conserved N-linked glycosylation site at residue Asn297 of the fragment crystallisable (Fc). Most of the mAbs approved by the EMA are commercialized as a complex mixture of glycoforms at this site. It is well stablished that the precise chemical structure of the N-linked glycan modulates the effector functions mediated by the Fc domain. Specifically, for cancer treatment applications, the lack of fucose on the glycan structure contributes to enhance the effector functions of the antibodies, via increased affinity of IgG1 for FcgRIIIa on immune cells. New strategies to glycoengineering mAbs with homogenous glycoforms and lacking fucose core on their glycan structures have become a priority for the biopharmaceutical industry in order to obtain “biosuperior” anticancer drugs. Here, we will engineer a novel fucosidase enzyme that can act on fully glycosylated mAbs in order to simplify the chemoenzymatic synthesis of antibody drugs, based on the host laboratory expertise in Carbohydrate Active Enzymes. We will address three specific aims: (1) to define the structural basis of EndoS antibody specificity; (2) to elucidate the molecular mechanisms of IgG defucosylation by AlfC; and (3) to engineer an enzyme with fucosidase activity and specific for IgG. The GlycoMabs project will provide me an excellent and unique career opportunity by learning new skills in structural biology, protein engineering and project management which will grant me a leading independent position. Moreover, I will explore the industry interest in the application of our novel enzymes to generate homogeneous and afucosylated antibodies through an intersectoral secondment. Altogether, we will contribute to construct the next generation of therapeutic glycoengineered mAbs to tailor the immune reactions and increase their clinical potency.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCOMABS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLYCOMABS" are provided by the European Opendata Portal: CORDIS opendata.
Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.
Read MoreMultimode cOrrelations in microwave photonics with Superconducting quAntum Circuits
Read More